Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis
- DOI
- 10.1016/j.suronc.2026.102600
- Published
- 2027-02
- Container
- Surgical Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.suronc.2026.102600,
title = {Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis},
author = {Yongqi Li and Xu Geng and Liulan Qian and Cheng Liu and Zhongzhi Jia},
year = {2027},
journal = {Surgical Oncology},
doi = {10.1016/j.suronc.2026.102600},
url = {https://doi.org/10.1016/j.suronc.2026.102600}
}RIS
TY - JOUR TI - Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis AU - Yongqi Li AU - Xu Geng AU - Liulan Qian AU - Cheng Liu AU - Zhongzhi Jia PY - 2027 JO - Surgical Oncology DO - 10.1016/j.suronc.2026.102600 UR - https://doi.org/10.1016/j.suronc.2026.102600 ER -
APA
Li, Y., Geng, X., Qian, L., Liu, C., & Jia, Z. (2027). Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis. Surgical Oncology. https://doi.org/10.1016/j.suronc.2026.102600
Source records
- crossref · retrieved 2026-11-10T16:41:22.639Z